et al., PLOS ONE, doi:10.1371/journal.pone.0247163 (preprint 11/3) (Peer Reviewed)
Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.
HCQ OR 0.56, p
Ivermectin OR 0.27, p
Vitamin C OR 0.82, p
Behera et al., 11/3/2020, retrospective, India, South Asia, peer-reviewed, 13 authors.
risk of COVID-19 case, 27.9% lower, RR 0.72, p = 0.29, treatment 7 of 19 (36.8%), control 179 of 353 (50.7%), adjusted per study, odds ratio converted to relative risk, model 2 conditional logistic regression.
risk of COVID-19 case, 26.3% lower, RR 0.74, p = 0.25, treatment 7 of 19 (36.8%), control 179 of 353 (50.7%), odds ratio converted to relative risk, matched pair analysis.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.